sq 24798 profile

2-mercaptomethyl-5-guanidinopentanoic acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	194328
CHEMBL ID	236822
SCHEMBL ID	5415499
MeSH ID	M0091153

Synonym
5-carbamimidamido-2-(sulfanylmethyl)pentanoic acid
2-mercaptomethyl-5-guanidinopentanoic acid
5-guanidino-2-(mercaptomethyl)pentanoic acid
(+/-)-5-guanidino-2-(mercaptomethyl)pentanoic acid
bdbm50201438
69734-02-7
CHEMBL236822 ,
sq-24798
5-(diaminomethylideneamino)-2-(sulfanylmethyl)pentanoic acid
sq-24,798
sq 24798
sq 24,798
SCHEMBL5415499
gtpl8656
70873-80-2
AKOS030556047
DTXSID40989901
Q27088854

Protein Targets (3)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carboxypeptidase B	Sus scrofa (pig)	IC50 (µMol)	0.0100	0.0100	0.0100	0.0100	AID305879
Carboxypeptidase B	Sus scrofa (pig)	Ki	0.0004	0.0004	0.0004	0.0004	AID304049
Carboxypeptidase N catalytic chain	Homo sapiens (human)	IC50 (µMol)	0.0020	0.0020	2.7010	5.4000	AID305880
Carboxypeptidase N catalytic chain	Homo sapiens (human)	Ki	0.0020	0.0020	0.0020	0.0020	AID304052
Carboxypeptidase B2	Homo sapiens (human)	IC50 (µMol)	0.0080	0.0015	0.5429	1.8000	AID305878
Carboxypeptidase B2	Homo sapiens (human)	Ki	0.0040	0.0040	0.2270	0.4500	AID304051
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Process	via Protein(s)	Taxonomy
bradykinin catabolic process	Carboxypeptidase N catalytic chain	Homo sapiens (human)
protein catabolic process	Carboxypeptidase N catalytic chain	Homo sapiens (human)
response to glucocorticoid	Carboxypeptidase N catalytic chain	Homo sapiens (human)
peptide metabolic process	Carboxypeptidase N catalytic chain	Homo sapiens (human)
protein processing	Carboxypeptidase N catalytic chain	Homo sapiens (human)
positive regulation of extracellular matrix constituent secretion	Carboxypeptidase B2	Homo sapiens (human)
blood coagulation	Carboxypeptidase B2	Homo sapiens (human)
response to xenobiotic stimulus	Carboxypeptidase B2	Homo sapiens (human)
negative regulation of plasminogen activation	Carboxypeptidase B2	Homo sapiens (human)
protein catabolic process	Carboxypeptidase B2	Homo sapiens (human)
negative regulation of fibrinolysis	Carboxypeptidase B2	Homo sapiens (human)
cellular response to glucose stimulus	Carboxypeptidase B2	Homo sapiens (human)
liver regeneration	Carboxypeptidase B2	Homo sapiens (human)
negative regulation of hepatocyte proliferation	Carboxypeptidase B2	Homo sapiens (human)
proteolysis	Carboxypeptidase B2	Homo sapiens (human)
fibrinolysis	Carboxypeptidase B2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Process	via Protein(s)	Taxonomy
protein binding	Carboxypeptidase N catalytic chain	Homo sapiens (human)
zinc ion binding	Carboxypeptidase N catalytic chain	Homo sapiens (human)
metallocarboxypeptidase activity	Carboxypeptidase N catalytic chain	Homo sapiens (human)
zinc ion binding	Carboxypeptidase B2	Homo sapiens (human)
metallocarboxypeptidase activity	Carboxypeptidase B2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Process	via Protein(s)	Taxonomy
extracellular region	Carboxypeptidase N catalytic chain	Homo sapiens (human)
extracellular space	Carboxypeptidase N catalytic chain	Homo sapiens (human)
extracellular region	Carboxypeptidase B2	Homo sapiens (human)
extracellular exosome	Carboxypeptidase B2	Homo sapiens (human)
extracellular space	Carboxypeptidase B2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay ID	Title	Year	Journal	Article
AID305880	Inhibition of human carboxypeptidase N	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa).
AID304050	Selectivity for porcine pancreatic carboxypeptidase B over bovine pancreatic carboxypeptidase A	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
AID304049	Inhibition of porcine pancreatic carboxypeptidase B	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
AID304052	Inhibition of human plasma carboxypeptidase N	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
AID305878	Inhibition of human activated thrombin activatable fibrinolysis inhibitor	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa).
AID305879	Inhibition of porcine pancreatic carboxypeptidase B	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa).
AID304051	Inhibition of human TAFIa	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
AID1345703	Human Carboxypeptidase B2 (plasma) (M14: Carboxypeptidase A)	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
AID1345390	Human Carboxypeptidase N, polypeptide 1 (M14: Carboxypeptidase A)	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3 (60.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.34 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.14 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
3-mercaptopropionic acid 3-Mercaptopropionic Acid: An inhibitor of glutamate decarboxylase. It decreases the GAMMA-AMINOBUTYRIC ACID concentration in the brain, thereby causing convulsions.. 3-mercaptopropanoic acid : A mercaptopropanoic acid that is propanoic acid carrying a sulfanyl group at position 3.	2.65	3	mercaptopropanoic acid	algal metabolite
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	1.96	1	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
2-mercaptomethyl-3-guanidinoethylthiopropionic acid 2-mercaptomethyl-3-guanidinoethylthiopropionic acid: RN given refers to (+-)-isomer; structure given in first source	1.96	1
sq 14,603 2-benzyl-3-mercaptopropanoic acid: structure; carboxypeptidase inhibitor	2.66	3
bradykinin [no description available]	1.96	1	oligopeptide	human blood serum metabolite; vasodilator agent

Condition	Relationship Strength	Studies
Thromboembolism, Venous [description not available]	2.03	1
Blood Loss, Surgical Loss of blood during a surgical procedure.	2.03	1
Venous Thromboembolism Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.	2.03	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	1.96	1

sq 24798

Description

Cross-References

Synonyms (18)

Protein Targets (3)

Inhibition Measurements

Biological Processes (15)

Molecular Functions (3)

Ceullar Components (3)

Bioassays (9)

Research

Studies (5)

Market Indicators

Research Demand Index: 12.34

Study Types

sq 24798

Description

Cross-References

Synonyms (18)

Protein Targets (3)

Inhibition Measurements

Biological Processes (15)

Molecular Functions (3)

Ceullar Components (3)

Bioassays (9)

Research

Studies (5)

Market Indicators

Research Demand Index: 12.34

Study Types

Related Drugs (5)

Related Conditions (4)